We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cencora (COR - Free Report) is well-poised for growth on the back of a robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern.
This Zacks Rank #2 (Buy) company’s shares have lost 9.7% in the year-to-date period compared with the industry’s 1.8% drop. However, the S&P 500 Index has gained 7.4% in the same time frame.
Cencora is one of the world’s largest pharmaceutical service companies. It is focused on providing drug distribution and related services to reduce healthcare costs and improve patient outcomes. The company has a market capitalization of $58.48 billion.
COR’s bottom line is anticipated to improve 10.1% over the next five years. Its earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 1.6%.
Image Source: Zacks Investment Research
Let’s delve deeper.
Positive Factors Driving COR’s Prospects
Specialty Expansion and MSO Strategy Support Long-Term Growth: Cencora continues to strengthen its position in specialty pharmaceuticals, a market expected to account for more than half of U.S. drug spending in the coming years. During the second-quarter earnings call, management highlighted progress in integrating OneOncology, acquired in February 2026, with Retina Consultants of America (RCA). Management is leveraging both platforms by sharing capabilities in clinical research, trial support and back-office services, creating a scalable specialty care ecosystem. These investments complement Cencora's broader strategy of deepening manufacturer partnerships while expanding services to community providers, positioning the company to benefit from growing demand for oncology, retina and other specialty therapies.
Pharmaceutical Supply Chain Leadership and Expanding Market Opportunity: Cencora's pharmaceutical-centric strategy remains a competitive advantage. The company continues investing in automated fulfillment centers, digital infrastructure and AI-supported tools that improve inventory management, customer visibility and operational efficiency across the pharmaceutical supply chain. These capabilities reinforce Cencora's role as a critical partner for manufacturers and healthcare providers while supporting long-term customer relationships.
The long-term demand backdrop also remains favorable. Industry forecasts project U.S. pharmaceutical spending to grow at an 8.2% CAGR through 2028, supported by rising prescription volumes, specialty therapies and broader patient access. Cencora is well positioned to benefit from sustained GLP-1 utilization, which contributed nearly $1.9 billion of year-over-year sales growth during the quarter despite moderating growth expectations.
International Business and Specialty Logistics Continue to Improve: Cencora's International Healthcare Solutions segment remained another bright spot. International revenues increased 13% year over year, while operating income rose 13.7%, driven by strong European distribution performance and a second consecutive quarter of operating income growth in global specialty logistics. Management highlighted new contract wins in cell and gene therapies, laboratory logistics and continued momentum at World Courier, reflecting improving execution in complex pharmaceutical logistics.
Key Challenges for COR Stock
Revenue Mix and Pricing Headwinds Could Pressure Reported Growth: Although prescription demand remains healthy, several factors continue to weigh on reported revenue growth. During the second quarter, manufacturer list price reductions created a roughly $2 billion revenue headwind, while faster-than-expected brand conversions at a large mail-order customer and slower GLP-1 growth prompted management to lower full-year revenue guidance. While these factors have a limited effect on operating income because they primarily involve lower-margin products, they can create volatility in reported sales growth and investor sentiment.
Higher Debt and Ongoing Regulatory Risks Remain Watch Points: The OneOncology acquisition has strengthened Cencora's specialty platform but also increased leverage. Net interest expense rose following the acquisition, and management expects approximately $485 million of interest expense in fiscal 2026 despite continued debt repayment efforts.
Beyond leverage, Cencora operates in a highly regulated pharmaceutical distribution environment. Ongoing opioid-related litigation exposure, controlled-substance monitoring requirements and evolving healthcare reimbursement policies could increase compliance costs or create operational challenges, even as the company continues investing in supply-chain integrity and regulatory compliance.
COR has been witnessing a stable estimate revision trend for fiscal 2026. In the past 30 days, the Zacks Consensus Estimate for earnings has remained stable at $17.79 per share.
The consensus mark for third-quarter fiscal 2026 revenues is pegged at $84.89 billion, indicating a 5.2% improvement from the year-ago reported actuals. The bottom-line estimate is pinned at $4.37, implying year-over-year growth of 9.2%.
West Pharmaceutical has an estimated long-term earnings growth rate of 14.4%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%.
West Pharmaceutical’s shares have gained 29.2% against the industry’s 1.6% decline in the year-to-date period.
Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.
Cardinal Health’s shares have risen 9.9% against the industry’s 1.6% decline in the year-to-date period.
McKesson has a long-term estimated growth rate of 13.7%. MCK’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.1%.
McKesson’s shares have edged up 0.5% against the industry’s 1.6% decline in the year-to-date period.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why You Should Add Cencora Stock to Your Portfolio Now
Key Takeaways
Cencora (COR - Free Report) is well-poised for growth on the back of a robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern.
This Zacks Rank #2 (Buy) company’s shares have lost 9.7% in the year-to-date period compared with the industry’s 1.8% drop. However, the S&P 500 Index has gained 7.4% in the same time frame.
Cencora is one of the world’s largest pharmaceutical service companies. It is focused on providing drug distribution and related services to reduce healthcare costs and improve patient outcomes. The company has a market capitalization of $58.48 billion.
COR’s bottom line is anticipated to improve 10.1% over the next five years. Its earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 1.6%.
Image Source: Zacks Investment Research
Let’s delve deeper.
Positive Factors Driving COR’s Prospects
Specialty Expansion and MSO Strategy Support Long-Term Growth: Cencora continues to strengthen its position in specialty pharmaceuticals, a market expected to account for more than half of U.S. drug spending in the coming years. During the second-quarter earnings call, management highlighted progress in integrating OneOncology, acquired in February 2026, with Retina Consultants of America (RCA). Management is leveraging both platforms by sharing capabilities in clinical research, trial support and back-office services, creating a scalable specialty care ecosystem. These investments complement Cencora's broader strategy of deepening manufacturer partnerships while expanding services to community providers, positioning the company to benefit from growing demand for oncology, retina and other specialty therapies.
Pharmaceutical Supply Chain Leadership and Expanding Market Opportunity: Cencora's pharmaceutical-centric strategy remains a competitive advantage. The company continues investing in automated fulfillment centers, digital infrastructure and AI-supported tools that improve inventory management, customer visibility and operational efficiency across the pharmaceutical supply chain. These capabilities reinforce Cencora's role as a critical partner for manufacturers and healthcare providers while supporting long-term customer relationships.
The long-term demand backdrop also remains favorable. Industry forecasts project U.S. pharmaceutical spending to grow at an 8.2% CAGR through 2028, supported by rising prescription volumes, specialty therapies and broader patient access. Cencora is well positioned to benefit from sustained GLP-1 utilization, which contributed nearly $1.9 billion of year-over-year sales growth during the quarter despite moderating growth expectations.
International Business and Specialty Logistics Continue to Improve: Cencora's International Healthcare Solutions segment remained another bright spot. International revenues increased 13% year over year, while operating income rose 13.7%, driven by strong European distribution performance and a second consecutive quarter of operating income growth in global specialty logistics. Management highlighted new contract wins in cell and gene therapies, laboratory logistics and continued momentum at World Courier, reflecting improving execution in complex pharmaceutical logistics.
Key Challenges for COR Stock
Revenue Mix and Pricing Headwinds Could Pressure Reported Growth: Although prescription demand remains healthy, several factors continue to weigh on reported revenue growth. During the second quarter, manufacturer list price reductions created a roughly $2 billion revenue headwind, while faster-than-expected brand conversions at a large mail-order customer and slower GLP-1 growth prompted management to lower full-year revenue guidance. While these factors have a limited effect on operating income because they primarily involve lower-margin products, they can create volatility in reported sales growth and investor sentiment.
Higher Debt and Ongoing Regulatory Risks Remain Watch Points: The OneOncology acquisition has strengthened Cencora's specialty platform but also increased leverage. Net interest expense rose following the acquisition, and management expects approximately $485 million of interest expense in fiscal 2026 despite continued debt repayment efforts.
Beyond leverage, Cencora operates in a highly regulated pharmaceutical distribution environment. Ongoing opioid-related litigation exposure, controlled-substance monitoring requirements and evolving healthcare reimbursement policies could increase compliance costs or create operational challenges, even as the company continues investing in supply-chain integrity and regulatory compliance.
Cencora, Inc. Price
Cencora, Inc. price | Cencora, Inc. Quote
Estimate Trend
COR has been witnessing a stable estimate revision trend for fiscal 2026. In the past 30 days, the Zacks Consensus Estimate for earnings has remained stable at $17.79 per share.
The consensus mark for third-quarter fiscal 2026 revenues is pegged at $84.89 billion, indicating a 5.2% improvement from the year-ago reported actuals. The bottom-line estimate is pinned at $4.37, implying year-over-year growth of 9.2%.
Other Stocks to Consider
Some other top-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Cardinal Health (CAH - Free Report) and McKesson (MCK - Free Report) , each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
West Pharmaceutical has an estimated long-term earnings growth rate of 14.4%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%.
West Pharmaceutical’s shares have gained 29.2% against the industry’s 1.6% decline in the year-to-date period.
Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.
Cardinal Health’s shares have risen 9.9% against the industry’s 1.6% decline in the year-to-date period.
McKesson has a long-term estimated growth rate of 13.7%. MCK’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.1%.
McKesson’s shares have edged up 0.5% against the industry’s 1.6% decline in the year-to-date period.